2 weeks Ago By ABMN Staff
Envestnet Asset Management Inc. boosted its holdings in Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
The firm owned 87,195 shares of the biotechnology company’s stock after buying an additional 910 shares during the period. Envestnet Asset Management Inc.’s holdings in Ligand Pharmaceuticals were worth $9,343,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. Smartleaf Asset Management LLC grew its stake in shares of Ligand Pharmaceuticals by 119.5% during the fourth quarter.
Smartleaf Asset Management LLC now owns 406 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 221 shares during the period. US Bancorp DE grew its position in shares of Ligand Pharmaceuticals by 14.8% during the 4th quarter.
US Bancorp DE now owns 758 shares of the biotechnology company’s stock worth $81,000 after buying an additional 98 shares during the period. KBC Group NV increased its stake in shares of Ligand Pharmaceuticals by 49.7% in the 4th quarter.
KBC Group NV now owns 904 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 300 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Ligand Pharmaceuticals in the 4th quarter valued at approximately $172,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Ligand Pharmaceuticals during the 3rd quarter worth approximately $180,000.
Institutional investors and hedge funds own 91.28% of the company’s stock. Ligand Pharmaceuticals Stock Up 0.
3 % Shares of LGND opened at $104.97 on Friday. Ligand Pharmaceuticals Incorporated has a twelve month low of $67.
72 and a twelve month high of $129.90. The stock has a market capitalization of $2.
02 billion, a P/E ratio of 41.82 and a beta of 1.07.
The company has a 50 day moving average of $109.82 and a 200-day moving average of $112.10.
Analyst Ratings Changes Check Out Our Latest Stock Analysis on LGND Insider Buying and Selling In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 5,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $115.03, for a total transaction of $575,150.
00. Following the sale, the chief financial officer now directly owns 18,879 shares of the company’s stock, valued at $2,171,651.37.
The trade was a 20.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link .
5.90% of the stock is currently owned by corporate insiders. Ligand Pharmaceuticals Company Profile ( Free Report ) Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. Read More Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ).
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
